EUROTOX 2018, Brussels, Belgium | Programme, January, 2018 1 Sunday, 2 September, 2018 08h00 - 21h00 Congress registration 16h00 – 21h00 Exhibition 10h30–16h00 Continuing Education Courses (CEC), including coffee & lunch breaks 10h30–16h00 Meeting Stu- dio 311 CEC1 Exposure, hazard and risk assessment of mixtures of pesticides/chemicals in food using the tools developed in the EuroMix project Chairs: Hubert Dirven, Norway | Jacob van Klaveren, The Netherlands Risk assessment of chemical mixtures – Regulatory requirements and current scientific approaches Roland Solecki, BfR, Germany Industry perspective on mixture risk assessment Heli Hollnagel, DOW chemical, Switzerland Real-life dietary exposures to pesticides: An exposure driven test strategy Jacob van Klaveren, RIVM, The Netherlands Case study: combining dietary and non-dietary pesticide exposure Marc Kennedy, Fera Science Limited, United Kingdom Case study: Aggregate and cumulative consumer exposure to bisphenols Cecilie Karrer, EHTZ, Switzerland Case study: Exposure to mixtures of chemicals in a human study and verification of models using real-life data Monica Andreassen, Norwegian Institute of Public Health, Norway 10h30–16h00 Meeting Stu- dio 312 CEC2 Introduction to benchmark dose modelling using the PROAST software Chairs: Wout Slob, The Netherlands |Allen Davis, United States Difference between NOAEL and BMD approach | Introduction to the BMD method Wout Slob, RIVM, The Netherlands
08h00 - 21h00 Congress registration 16h00 – 21h00 Exhibition
10h30–16h00 Continuing Education Courses (CEC), including coffee & lunch breaks
10h30–16h00 Meeting Stu-dio 311
CEC1 Exposure, hazard and risk assessment of mixtures of pesticides/chemicals in food using the tools developed in the EuroMix project Chairs: Hubert Dirven, Norway | Jacob van Klaveren, The Netherlands Risk assessment of chemical mixtures – Regulatory requirements and current scientific approaches Roland Solecki, BfR, Germany Industry perspective on mixture risk assessment Heli Hollnagel, DOW chemical, Switzerland Real-life dietary exposures to pesticides: An exposure driven test strategy Jacob van Klaveren, RIVM, The Netherlands Case study: combining dietary and non-dietary pesticide exposure Marc Kennedy, Fera Science Limited, United Kingdom Case study: Aggregate and cumulative consumer exposure to bisphenols Cecilie Karrer, EHTZ, Switzerland Case study: Exposure to mixtures of chemicals in a human study and verification of models using real-life data Monica Andreassen, Norwegian Institute of Public Health, Norway
10h30–16h00 Meeting Stu-dio 312
CEC2 Introduction to benchmark dose modelling using the PROAST software Chairs: Wout Slob, The Netherlands |Allen Davis, United States Difference between NOAEL and BMD approach | Introduction to the BMD method Wout Slob, RIVM, The Netherlands
Differences between EPA and EFSA approach Allen Davis, MSPH, United States Presentation of the PROAST webtool Jose Cortinas Abrahantes, EFSA, Italy Practical exercises with the PROAST webtool: data table generation Bas Bokkers, RIVM, The Netherlands Practical exercises with the PROAST webtool: Presentation of case studies and modelling of provided datasets Philip Bellion, DSM Nutritional Products, Switzerland
10h30–16h00 Meeting Stu-dio 313
CEC3 Application of non-animal (toxico)kinetic data and tools in risk assessment from basic research to practice Chairs: Alicia Paini, Italy | Cecilia Tan, United States Incorporating TK data and tools to support regulatory decision making – from the perspectives of EPA Cecilia Tan, EPA, United States Incorporating TK data and tools to support regulatory decision making – from the perspectives of cosmetic industry Martina Klaric, Cosmetics Europe, Belgium Developing TK databases and tools to support food safety assessment Jean Lou Dorne, EFSA, Italy Incorporating TK data and tools to support regulatory decision making – a European perspective Minne Heringa, RIVM, The Netherlands Predictive tools and databases for TK Judith Madden, LJMU, United Kingdom RVis: a freely available modelling platform George Loizou, HSE’s Health & Safety Laboratory, United Kingdom
CEC4 Organ-specific in vitro modelling: state-of-the-art Chairs: Mathieu Vinken, Belgium |Arno Gutleb, Luxembourg Liver-based in vitro models for toxicity testing Vinken Mathieu, Vrije Universiteit Brussels, Belgium Kidney-based in vitro models for toxicity testing Paul Jennings, Innsbruck Medical University, Austria Lung-based in vitro models for toxicity testing Samuel Constant, Epithelix Sàrl, Switzerland Stem cell-based in vitro models for toxicity testing Joery De Kock, Vrije Universiteit Brussels, Belgium Tridimensional models for in vitro toxicity testing Arno Gutleb, Luxembourg Institute of Science and Technology, Luxembourg Dynamic organ-on-chip models for in vitro toxicity testing Yaakov Nahmias, The Hebrew University of Jerusalem, Israel
10h30–16h00 Meeting Stu-dio 314+316
CEC5 Read-across in REACH and its assessment Chairs: David Bell, Finland | Sabine Van Miert, Belgium Read-across in REACH and the read-across assessment framework Agnes Kovari, ECHA, Hungary Scientific considerations for assessing read-across between multi-constituent or UVCB substances Eric Stilgenbauer, ECHA, France
Scientific issues that need to be addressed for a successful read-across prediction Mark Cronin, Liverpool John Moores University, United Kingdom Use of novel and alternative methods to support read-across Bob van de Water, University of Leiden, Netherlands Key issues for successful read-across – a user's guide Nicholas Ball, Dow Europe GmbH, Switzerland
HALF DAY 13h00–16h00 Meeting Stu-dio 315
CEC6 Creating quantitative Adverse Outcome Pathways (AOPs) Organized and supported by OECD
Chairs: Anne Gourmelon, France | Magdalini Sachana, France Introduction and best practices in building AOPs Anne Gourmelon, OECD, France Running Effectopedia for the first time Searching and exploring Effectopedia content Creating an AOP in Effectopedia Magdalini Sachana, OECD, France Add quantitative information to a key event and derive key event relationship within an AOP Transforming test data (in-vitro to in-vivo) Using in-silco models (R or MATLAB) Hristo Aladjov, OECD, France
13h00–16h00 Meeting Stu-dio 211+212
EU-ToxRisk: status quo of the Horizon2020 flagship project on non-animal toxicology
17h00–19h00 GOLD Hall
Opening Ceremony including Keynote lecture: Consumer toxicology: Natural is good, synthetic is bad Michael Siegrist, Switzerland and EUROTOX Merit Award
19h00-21h00 Welcome Reception in the Exhibition Area
Session 1 Organs on a chip in toxicology - is the end of animal testing near? Chairs: Adrian Roth, Switzerland | Vera Rogiers, Belgium The potential of organs on chips to impact drug safety assessment Adrian Roth, Roche Innovation Center Basel, Switzerland The role of cross-species microphysiological systems in understanding target organ toxicity in oncology drug projects Lorna Ewart, Astra-Zeneca, United Kingdom Organs on chips for toxicity testing: Lung-thrombosis-chip as a practical example. Monicah Otieno, Janssen Pharmaceuticals Research & Development, United States of America A microfluidic intestinal model to investigate altered drug behaviour under disease condition Annie Moisan, Roche Innovation Center Basel, Switzerland Adult stem cell patient derived toxicology models in organoids Robert Vries, Hubrecht Institute, The Netherlands
10h00–12h00 COPPER Hall
Session 2 Ensuring validity of in vitro replacements: what is needed for regulatory decision making? Chairs: Heather Wallace, United Kingdom | Ruth Roberts, United Kingdom The current paradigm on data requirements: what is possible and what is not Diane Benford, Food Standards Agency, United Kingdom In vitro alternatives: progress, challenges and opportunities Ian Kimber, University of Manchester, United Kingdom
A framework of a fit for purpose evaluation of non-animal methods Douglas Wolf, Syngenta, United States of America Case Study 1: Chemicals Hans Ketelsegers, ConCawe, Belgium Case Study 2: Agrichemicals Phil Botham, Syngenta, United Kingdom Case Study 3: Personal care or pharmaceuticals Carl Westmoreland, Unilever, United Kingdom Panel discussion all speakers
10h00–12h00 SILVER Hall
Session 3 Chemical-induced immunosuppression in the 21st century Chairs: François Huaux, Belgium | Emanuela Corsini, Italy Future direction in immunotoxicology: immunosuppression as key player François Huaux, Université catholique de Louvain, Belgium Pesticide-induced immunotoxicity: the experience at EFSA Andrea Terron, EFSA, Italy Chemical-induced immunotoxicity: the experience at NTP Dori Germolec, NIEHS, United States of America Immunosuppression mediated by enzymes that degrade tryptophan Benoît Van den Eynde, Univeristé catholique de Louvain, Belgium The aryl hydrocarbon receptor in immunity: tools and potential Charlotte Esser, Leibniz Research Institute for Environmental Medicine (IUF), Germany
Session 4 Non-clinical pharmacology and toxicology assessment of monoclonal antibodies supporting human clinical trials Chairs: Annick Cauvin, Belgium| Thomas Weiser, Switzerland Current strategies in the safety assessment of monoclonal antibodies Sven Kronenberg, Roche, Switzerland The general relevance of NHP models for safety assessment of mAbs Gerhard Weinbauer, Covance, Germany In vitro pharmacology and safety testing of monoclonal antibodies Andrea Kiessling, UCB, United Kingdom The use of in vitro and in vivo pharmacology and safety data to set safe starting doses for FIH studies with monoclonal antibodies Lolke De Haan , Medimmune, United Kingdom
Session 5 Oligonucleotides – do they warrant specific safety assessment?
Chairs: Yann Tessier, Denmark | Annemieke Aartsma-Rus, The Netherlands Overview of ways oligonucleotides can be exploited as therapeutics Annemieke Aartsma-Rus, Leiden University Medical Center, The Netherlands How do ADME properties of oligonucleotides influence their therapeutic index? Steve R. Hood, Glaxosmithkline, United Kingdom Antisense oligonucleotides – recent advances in preclinical safety assessment Matthias Festag, F. Hoffmann-La Roche, Switzerland
Non-clinical aspects of oligonucleotide drug development: a regulator's perspective David Jones, The Medicines & Healthcare Products Regulatory Agency, United Kingdom
14h00–16h00 COPPER Hall
Session 6: Microphysiological human stem cell systems for toxicity testing Chairs: Tamara Vanhaecke, Belgium | Sandra Coecke, Italy New developments in human stem cell-based models for toxicity testing Jan Hengstler, Leibniz Institut für Arbeitsforschung an der Technischen Universität Dortmund - IfADo, Germany Human skin-derived precursors and their applications in hepatic toxicology Robim Marcelino Rodrigues, Vrije Universiteit Brussels, Belgium A human brain microphysiological iPSC-derived system to study neurotoxicity Helena Hogberg, United States of America What is new in the use of embryonal stem cells for cardiotoxicity testing? Jürgen Hescheler, University Hospital Cologne, Institute for Neurophysiology, Germany Good in vitro method practices as (the) key for regulatory acceptance of stem cell-derived toxicity methods Sandra Coecke, EURL-ECVAM, Italy
14h00–16h00 SILVER Hall
Session 7 Detecting immunotoxicity of nanomaterials: from in vitro to rapid predictive testing Chairs: Diana Boraschi, Italy | Albert Duschl, Austria In vitro models for assessing nanomaterial functional interaction with human immunological and non-immunological barriers Claus-Michael Lehr, Helmholtz Institute of Pharmacological Research Saarland, Germany Advanced models and detection systems for evaluating immunotoxicity of nanomaterials in health and disease Yvonne Kohl, Fraunhofer Institute for Biomedical Engineering, Germany Immune response-on-chip: microfluidic systems for detecting human immune and inflammatory response to nanomaterials Peter Ertl, Technical University Vienna, Austria
Towards realistic in vitro models for prediction of nanomaterials’ immunotoxicity and impact on immune system development Inge Nelissen, Vlaamse Instelling voor Technologisch Onderzoek (VITO), Belgium
14h00–16h00 The Arc
Session 8 Systems-biology-based 3R methods in toxicology Chairs: Angela Mally, Germany | Katrin Schutte, Belgium Single cell imaging for quantitative systems toxicology of hepatoxicity Bob van de Water, Leiden Academic Centre for Drug Research (LACDR), The Netherlands Integration of mechanism-based in vitro methods and quantitative in vitro-in vivo extrapolation (QIVIVE) modelling for prediction of nephrotoxicity Angela Mally, University of Würzburg, Germany A 3R systems biology strategy for human neurotoxicity hazard, risk and safety assessment Remco Westerink, Utrecht University, Institute for Risk Assessment Sciences, The Netherlands Gaining confidence in replacing animal tests: a case study of the endocrine disruption program at the US EPA Richard Judson, US EPA, National Center for Computational Toxicology, United States of America
14h00–16h00 Hall 300
Session 9 Open Source Platforms in chemical risk assessment: means to translate 21st century research and tools to the risk assessment community? Chairs: Harvey Clewell, United States of America| Jean Lou Dorne, Italy In vitro models and opensource toxicokinetic databases to support quantitative in vitro to in vivo extrapolation for human risk as-sessment Harvey Clewell, ScitoVation, United States of America Advancing risk assessment of cosmetics using in silico modelling and the COSMOS database Alicia Paini, JRC-ECVAM, Italy Reconnecting exposure, toxicokinetics and toxicity in food safety: opendfoodtox and TKplate for human health, animal health and ecological risk assessment
Jean Lou Dorne, EFSA, Italy Opensource repositeries for the integration of aggregated exposure pathways and adverse outcome pathways Cecilia Tan, US-EPA, United States of America
Session10 Mechanism-based mitochondrial toxicity testing for chemical safety evaluation Chairs: Bob van de Water, The Netherlands | Philippe Vanparys, Belgium Target tissue specific activation of transcriptional programmes by mitotoxicants Marcel Leist, University of Konstanz, Germany Mechanism-based high throughput screening of mitotoxicity in the Tox21 program Steve Simmons, National Center for Computational Toxicology / U.S. EPA Office of Research and Development, United States of America Quantitative assessment of mitochondrial toxicity and oxidative stress interaction in Adverse Outcome Pathways Bob van de Water, Leiden University, The Netherlands In silico modelling of mitochondrial toxicity and oxidative stress to define the tipping point between adaptive and adverse effects Andrew White, Safety & Environmental Assurance Centre / Unilever, United Kingdom
The bright and the dark sides of Nrf2 in skin biology and pathology Sabine Werner, ETH Zurich, Switzerland Nrf2/ARE signaling pathway is a key factor for colorectal cancer Laurence Huc, TOXALIM Research Center in Food Toxicology, France Nrf2 pathway controls ROS-induced skin fibrosis
Frédéric Batteux, INSERM, Institut Cochin, France Physiology, pharmacology and toxicology of the Nrf2 pathway Ian Copple, University of Liverpool, United Kingdom
16h30-18h30 SILVER Hall
Session 12: Old drugs in new guises: the toxicology of repurposing Chairs: Ruth Roberts, United Kingdom | Miranda Cornet, Belgium Repurposing of new medicines: opportunities and challenges Ruth Roberts, University of Birmingham, United Kingdom Potential reuse of oncology drugs in the treatment of rare diseases Weida Tong, FDA NCTR, United States of America Rethinking immunotherapy for neurodegenerative diseases Ron Tjalkens, Colorado State University, United States of America New opportunities for psychoactives in psychiatry Paul Duffy, ApconiX, United Kingdom
16h30–18h30 The Arc
Session 13 Air pollution over and beyond the classical risk factors Chairs: Tim Nawrot, Belgium | Jordi Sunyer, Spain European air pollution models Gerard Hoek, Utrecht University, The Netherlands Traffic exposure and health effects in persons with asthma Paul Cullinan, Imperial College London, United Kingdom Carbon load in airway macrophages as a biomarker of chronic exposure to air pollution Ben Nemery, University of Leuven, Belgium
Early life time windows of environmental neurotoxicity Jordi Sunyer, CREAL, Spain Air pollution stress and the ageing phenotype Tim Nawrot, Hasselt University, Belgium
Session 14 Ecotoxicology and toxicology: bridging the gaps | models and frameworks Chairs: Dries Knapen, Belgium |Alan Boobis, United Kingdom Example 1: Pathway approaches Ecotoxicology Lucia Vergauwen, University of Antwerp, Belgium Toxicology Mathieu Vinken, Vrije Universiteit Brussels, Belgium Example 2: Mixtures Ecotoxicology Ad Ragas, UNijmegen, The Netherlands Toxicology Jean-Lou Dorne, EFSA, Italy Panel discussion All speakers
10h00–12h00 COPPER Hall
Session 15: Developing safe medicines for children – non-clinical considerations Chairs: Luc De Schaepdrijver, Belgium |Miranda Cornet, Belgium Postnatal development of organ systems – species comparison Steven Van Cruchten, University of Antwerp, Belgium
Developmental changes in drug disposition and response: the challenges Jean-Marie Nicolas, UCB Biopharma, Belgium What can we do better in bringing safe medicines to children – an industry perspective Georg Schmitt, Roche, Switzerland Non-clinical safety considerations to support pediatric drug development – a regulatory update Paul Baldrick, Covance, United Kingdom
10h00–12h00 SILVER Hall
Session 16 Innovative medicinal products – challenges for the safety assessment of adverse immune effects Chairs: Marc Pallardy, France | Peter Hoet, Belgium Nanomedicinal products and immunotoxicity: pitfalls in testing and the regulatory framework Christina Giannakou, University Maastricht/RIVM, The Netherlands Immunotoxicity assessment of biotech products and small molecules Marc Pallardy, INSERM, University Paris-Sud, France Industry perspective on the challenges and opportunities of the safety assessment of biologicals Sjeng Horbach, Genmab, The Netherlands Regulatory view on immunotoxicity assessment of biomedical and biotechnology applications Ruben Pita, PharmD, LLM, United Kingdom
10h00–12h00 The Arc
Session 17 Adverse Outcome Pathways and development of alternative methods Supported by ECETOC
Chairs: Bennard van Ravenzwaay, Sweden | Aldert Piersma, The Netherlands Introduction and use of AOP in the European Union Maurice Whelan, EU, JRC – ECVAM, Italy Respiratory sensitization: in absence of an appropriate animal study, how can an AoP approach help
Ian Kimber, University of Manchester, United Kingdom Ontologies and AoP in developmental toxicity Thomas Knudsen, USA- EPA, United States of America AoP development at OECD – state of the art Magdalini Sachana, OECD, France
Session 18 Ecotoxicology and toxicology: bridging the gaps | contemporary challenges Chairs: Mark Martens, Belgium | Chair 2: tbc. Example 1: Nanomaterials Ecotoxicology Jérome Rose, CEREGE, France Toxicology Hans Bouwmeester, University Wageningen, The Netherlands Example 2: Metals Ecotoxicology Erik Smolders, Katholieke Universiteit Leuven, Belgium Toxicology Violaine Verougstaete, Eurométaux, Belgium Panel discussion All speakers
Session 19 Translational safety biomarkers: current and future trends Chairs: Andre da Costa, Belgium|Alain Verstraete, Belgium Evaluation of emerging safety biomarkers for major organ toxicities Heidrun Ellinger-Ziegelbauer, Bayer Pharma AG, Germany Recent advances on novel translational kidney safety biomarkers and their use in the value chain Jean-Charles Gautier, Sanofi R&D, France Taking safety biomarkers 'out of the box': biomarker panels and drug induced injuries Stephanie Glineur, UCB BioPharma, Belgium Transformative mechanism-based biomarkers of drug-induced liver injury and their application in precision toxicology Daniel Antoine, University of Liverpool, United Kingdom
14h00–16h00 SILVER Hall
Session 20 Tools, trends, and technologies in modern CNS safety assessment: mind your brain! Chairs: Marie-Luce Brodzinski-Rosseels, Belgium | Andrea Greiter-Wilke, Switzerland 3Rs-favorable CNS evaluation: Integration of safety pharmacology endpoints in toxicology studies Will Redfern, Astra Zeneca, United Kingdom Seizures and dreams in non-clinical drug development: from brain slices to EEG Simon Authier, CiToxLAB, Canada Do we neglect peripheral Neuropathy? Pathophysiology, assessment and translational aspects Joseph Arezzo, Albert Einstein College of Medicine, United States of America Exciting challenges in the regulatory field of preclinical abuse liability testing of novel CNS-active drug candidates: can we cope? Greet Teuns, Janssen Pharmaceutical N.V., Belgium
Session 21 New insights in the role of innate immunity in immunotoxicology Chairs: Raymond Pieters, The Netherlands | Marc Pallardy, France Role of innate immunity in drug induced hepatotoxicity Hartmut Jaeschke, University of Kansas Medical Centre, United States of America Monocytes in particle-induced lung fibrosis Francois Huaux, Université catholique de Louvain, Belgium Neutrophil activation in contact allergy Saadia Kerdine-Römer, Université Paris Sud, France Neutrophil-monocyte interplay in drug induced liver injury Raymond Pieters, IRAS - Utrecht University, The Netherlands
Session 22 Mode of action as a key in risk assessment of chemical carcinogens Chairs: Dieter Schrenk, Germany | Jan Vondracek, Czech Republic Predictability of carcinogenesis A. Wallace Hayes, Michigan State University, United States of America Current approaches to risk assessment of carcinogens Dieter Schrenk, University of Kaiserslautern, Germany Mode of action and human relevance of rodent liver tumours produced by nongenotoxic CAR and PPARα activators Brian G. Lake, University of Surrey, United Kingdom Multiple modes of action converge in carcinogenicity of polycyclic aromatic hydrocarbons Jan Vondracek, Institute of Biophysics CAS, Czech Republic
Session 23 Breeding IATAs for predicting DART by fusing high-dimensional data with biological knowledge Chairs: Aldert Piersma, The Netherlands | Philippe Vanparys, Belgium Developmental and reproductive toxicity testing – the next generation Manon Beekhuijzen, Charles River Laboratories Den Bosch B.V., The Netherlands AOP-informed tiered testing to predict DART risks during new chemical R&D Richard Currie, Syngenta Limited, United Kingdom Building an AOP based prenatal developmental toxicity ontology Aldert Piersma, National Institute for Public Health and the Environment RIVM, The Netherlands Integrative modelling and AOP-based simulation of developmental toxicity Thomas Knudsen, National Center for Computational Toxicology, US EPA/ORD, United States of America
16h30–18h30 SILVER Hall
Session 24 Cardiac safety: current state of the art Chairs: Mark Holbrook, United Kingdom | Ester Lovsin-Barle, Switzerland Current challenges and opportunities in cardiac safety: a clinical perspective Philip Sager, Stanford University, School of Medicine, United States of America Developing solutions to detect and avoid cardiovascular toxicity in the clinic Jean-Pierre Valentin, UCB Biopharma, Belgium Ion channel profiling of stem cell-derived cardiomyocytes: Useful reagents for automated patch-clamp? Michael Morton, ApconiX, United Kingdom Cardiac Safety: A regulatory perspective Krishna Prasad, MHRA London, United Kingdom
Session 25 Developmental immunotoxicity Chairs: Unni C. Nygaard, Norway |Ingo Bichlmaier, Finland Mechanisms of adult and developmental immunotoxicity Rodney Dietert, College of Veterinary Medicine, Cornell University, United States of America Adversity of changes in immune parameters and findings in developmental immunotoxicity studies Henk van Loveren, Maastricht University, The Netherlands Skin sensitisation and developmental immunotoxicity - are there any links? Katarzyna Malkiewicz, Swedish Chemicals Agency, Sweden Regulatory aspects under REACH relating to the developmental immunotoxicity (DIT) cohort in the extended one-generation re-productive toxicity study (EOGRTS) Ingo Bichlmaier, ECHA, Finland
16h30-18h30 Hall 300
Industry sessions
18h00 Closure of the exhibition
19h30 - 24h00 Congress dinner at AUTOWORLD Brussels
Keynote Lecture Drug discovery: if you want to see different results do things differently Ruth Roberts, University of Birmingham, United Kingdom
09h30–10h00 Coffee Break
10h00–12h00 COPPER Hall
Session 26 Success of toxicology applications in society: from science to regulation and to implementation Chairs: Jyrki Liesivuori, Finland | Aristidis Tsatsakis, Greece How modern toxicology serves the society? Thomas Hartung, Johns Hopkins Bloomberg School of Public Health, United States of America Is EU chemical policy reaching its goals? Björn Hansen, European Commission, Belgium/Norway How effectively toxicology saves environment and consumers? Vito Buonsante, Client Earth, Italy/Belgium Successful implementation of toxicology in occupational health? Jukka Takala, International Commission on Occupational Health, Singapore
10h00–12h00 SILVER Hall
Session 27 Integrating epidemiology and experimental toxicology to understand the risk of endocrine disrupting chemical mixtures on chil-dren Chairs: Mattias Öberg, Sweden | Corinne Charlier, Belgium To use epidemiological data for identification of EDC mixtures correlated to adverse health outcomes on growth and metabolism, neurodevelopment, and sexual development Carl-Gustaf Bornehag, Karlstad University, Sweden Identification of mechanisms underlying adverse health outcomes related to EDC mixtures using experimental animal and cell
models Barbara Demeneix, Centre National de la Recherche Scientifique (CNRS), France Mixture effects on mesenchymal stem cell differentiation in relation to low birth weight and obesity later in life Joëlle Rüegg, Karolinska Institutet, Sweden Transcriptomic and epigenomic profiling of human embryonic stem cells (hESC) during differentiation into neural progenitors ex-posed to EDC mixtures Giuseppe Testa, The European Institute of Oncology, Italy
10h00–12h00 The Arc
Session 28 Cytokine release assays: future directions Supported by ILSI Health and Environmental Sciences Institute (HESI)
Chairs: Lynn O'Donnell, United States of America |Brigitte Molinier, France
Reference reagents for a better harmonisation of Cytokine Release Assays Sandrine Vessillier, National Institute for Biological Standards and Control, United Kingdom Utility of Humanized mice for assessment of potential cytokine release Deborah Finco, Pfizer, United States of America Translational aspects of the cytokine release assay Daniel Weinstock, Janssen R&D, United States of America Regulatory perspective of CRA in particular with respect to co-administered biotherapeutics Gabriele Reichmann, Paul-Ehrlich-Institute, Germany
10h00–12h00 Hall 300
Short oral communications 3
12h00–13h00 COPPER Hall
HESI CITE Lecture (Camporesi S.) Ethical issues of CRISPR genome editing: human and non-human applications Silvia Camporesi, King’s College, London
